<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37046036</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>12</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer.</ArticleTitle><Pagination><StartPage>5924</StartPage><MedlinePgn>5924</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5924</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-33126-x</ELocationID><Abstract><AbstractText>Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Innovative treatment is required to improve overall survival rates for advanced NSCLC. Oncolytic virotherapy using enteroviruses has emerged as a promising anticancer strategy. To identify a novel, potent virotherapy with an improved safety profile, we assessed the oncolytic activity of 28 enteroviral strains and focused on coxsackievirus A11 (CVA11). CVA11 infection caused extensive oncolytic activity in all three of the examined human NSCLC cell lines, with high intercellular adhesion molecule-1 (ICAM-1) expression associated with greater CVA11-induced cytotoxicity. In vitro inhibition analysis using a pan-caspase inhibitor and western blot detection of cleaved poly (ADP-ribose) polymerase (PARP) indicated that apoptosis partly contributed to CVA11-driven cytotoxicity. CVA11 infection-induced immunogenic cell death in vitro was strongly suggested by substantial calreticulin expression and release of high mobility group box-1 protein (HMGB1). Moreover, in vivo treatment of human NSCLC xenografts with intratumoral CVA11 injection caused complete tumor regression in all treated mice, without significant weight loss. Our findings indicate that novel oncolytic virotherapy utilizing CVA11 may be less toxic and more effective than current treatments for human NSCLC, thus warranting further investigation in clinical trial settings, especially in combination with immunotherapy.</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of ALA Advanced Medical Research, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. hinoue@fukuoka-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Shohei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of ALA Advanced Medical Research, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Oncology, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of ALA Advanced Medical Research, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soda</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of ALA Advanced Medical Research, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>Kenzaburo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of ALA Advanced Medical Research, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan. taniken@iqb.u-tokyo.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>KT's Laboratory has been financially supported by Neo Pharma Japan Co., Ltd. KT is a scientific advisor and a major stockholder of NPT Co., Ltd, and a minor stockholder of Oncolys BioPharma Inc, Shinnihonseiyaku Co., Ltd., NPT Co., Ltd, and SymBio Pharmaceuticals Co., Ltd. HI receives remuneration from Jocavio Inc. as an advisor, is a stockholder in Jocavio Inc. SM is a stockholder of NPT Co., Ltd. KT, HI and SM hold a patent on CVA11 [PCT/UP2O13A061686, PCT/JP2013/061686]. The other authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37046036</ArticleId><ArticleId IdType="pmc">PMC10097657</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-33126-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-33126-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinier O, et al. Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients. Respir. Med. Res. 2020;77:46–54. doi: 10.1016/j.resmer.2019.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmer.2019.10.001</ArticleId><ArticleId IdType="pubmed">32036284</ArticleId></ArticleIdList></Reference><Reference><Citation>Masemann D, Boergeling Y, Ludwig S. Employing RNA viruses to fight cancer: Novel insights into oncolytic virotherapy. Biol. Chem. 2017;398:891–909. doi: 10.1515/hsz-2017-0103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2017-0103</ArticleId><ArticleId IdType="pubmed">28441138</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang C, et al. Oncolytic viral vectors in the era of diversified cancer therapy: From preclinical to clinical. Clin. Transl. Oncol. 2022 doi: 10.1007/s12094-022-02830-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12094-022-02830-x</ArticleId><ArticleId IdType="pmc">PMC9131313</ArticleId><ArticleId IdType="pubmed">35612653</ArticleId></ArticleIdList></Reference><Reference><Citation>Stobart CC, Moore ML. RNA virus reverse genetics and vaccine design. Viruses. 2014;6:2531–2550. doi: 10.3390/v6072531.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v6072531</ArticleId><ArticleId IdType="pmc">PMC4113782</ArticleId><ArticleId IdType="pubmed">24967693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Enterovirus A71 oncolysis of malignant gliomas. Mol. Ther. 2020;28:1533–1546. doi: 10.1016/j.ymthe.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.04.005</ArticleId><ArticleId IdType="pmc">PMC7264442</ArticleId><ArticleId IdType="pubmed">32304669</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, et al. A novel combination therapy for human oxaliplatin-resistant colorectal cancer using oxaliplatin and coxsackievirus A11. Anticancer Res. 2018;38:6121–6126. doi: 10.21873/anticanres.12963.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.12963</ArticleId><ArticleId IdType="pubmed">30396927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV-A71 vaccine licensure: A first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg. Microbes Infect. 2016;5:e75. doi: 10.1038/emi.2016.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.73</ArticleId><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72:2609–2621. doi: 10.1158/0008-5472.CAN-11-3185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-11-3185</ArticleId><ArticleId IdType="pubmed">22461509</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley S, et al. Applications of coxsackievirus A21 in oncology. Oncolytic Virother. 2014;3:47–55. doi: 10.2147/OV.S56322.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OV.S56322</ArticleId><ArticleId IdType="pmc">PMC4918364</ArticleId><ArticleId IdType="pubmed">27512662</ArticleId></ArticleIdList></Reference><Reference><Citation>Annels NE, et al. Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus. Mol. Ther. Oncolytics. 2018;9:1–12. doi: 10.1016/j.omto.2018.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2018.02.001</ArticleId><ArticleId IdType="pmc">PMC6035483</ArticleId><ArticleId IdType="pubmed">29989024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly EJ, Hadac EM, Greiner S, Russell SJ. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 2008;14:1278–1283. doi: 10.1038/nm.1776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1776</ArticleId><ArticleId IdType="pubmed">18953352</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X, et al. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol. Ther. 2010;18:544–551. doi: 10.1038/mt.2009.296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.296</ArticleId><ArticleId IdType="pmc">PMC2839424</ArticleId><ArticleId IdType="pubmed">20051938</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesniere A, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482–491. doi: 10.1038/onc.2009.356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2009.356</ArticleId><ArticleId IdType="pubmed">19881547</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulli T, Koskimies P, Hyypiä T. Molecular comparison of coxsackie A virus serotypes. Virology. 1995;212:30–38. doi: 10.1006/viro.1995.1450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1995.1450</ArticleId><ArticleId IdType="pubmed">7676647</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren DR, Dorahy DJ, Greive SJ, Burns GF, Barry RD. Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21. J. Virol. 1997;71:785–789. doi: 10.1128/JVI.71.1.785-789.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.71.1.785-789.1997</ArticleId><ArticleId IdType="pmc">PMC191118</ArticleId><ArticleId IdType="pubmed">8985417</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren DR, Williams DT, Barry RD. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J. Virol. 1997;71:9844–9848. doi: 10.1128/JVI.71.12.9844-9848.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.71.12.9844-9848.1997</ArticleId><ArticleId IdType="pmc">PMC230302</ArticleId><ArticleId IdType="pubmed">9371658</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintieri L, Fantin M, Vizler C. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv. Exp. Med. Biol. 2007;593:95–104. doi: 10.1007/978-0-387-39978-2_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-0-387-39978-2_10</ArticleId><ArticleId IdType="pubmed">17265720</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, et al. RIP1 is a central signaling protein in regulation of TNF-α/TRAIL mediated apoptosis and necroptosis during Newcastle disease virus infection. Oncotarget. 2017;8:43201–43217. doi: 10.1863/oncotarget.17970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1863/oncotarget.17970</ArticleId><ArticleId IdType="pmc">PMC5522139</ArticleId><ArticleId IdType="pubmed">28591723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, et al. Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene. 2021;40:4783–4795. doi: 10.1038/s41388-021-01869-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-021-01869-4</ArticleId><ArticleId IdType="pubmed">34155344</ArticleId></ArticleIdList></Reference><Reference><Citation>Conos SA, et al. Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc. Natl. Acad. Sci. U S A. 2017;114:E961–E969. doi: 10.1073/pnas.1613305114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1613305114</ArticleId><ArticleId IdType="pmc">PMC5307433</ArticleId><ArticleId IdType="pubmed">28096356</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz RM, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 2007;67:2840–2848. doi: 10.1158/0008-5472.CAN-06-3974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-3974</ArticleId><ArticleId IdType="pubmed">17363607</ArticleId></ArticleIdList></Reference><Reference><Citation>Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994;12:991–1045. doi: 10.1146/annurev.iy.12.040194.005015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.iy.12.040194.005015</ArticleId><ArticleId IdType="pubmed">8011301</ArticleId></ArticleIdList></Reference><Reference><Citation>Prestwich RJ, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res. 2008;14:7358–7366. doi: 10.1158/1078-0432.CCR-08-0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-08-0831</ArticleId><ArticleId IdType="pmc">PMC2701231</ArticleId><ArticleId IdType="pubmed">19010851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotteas EA, et al. The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: Implications for disease progression and prognosis. Anticancer Res. 2014;34:4665–4672.</Citation><ArticleIdList><ArticleId IdType="pubmed">25202042</ArticleId></ArticleIdList></Reference><Reference><Citation>Roland CL, Harken AH, Sarr MG, Barnett CC. ICAM-1 expression determines malignant potential of cancer. Surgery. 2007;141:705–707. doi: 10.1016/j.surg.2007.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2007.01.016</ArticleId><ArticleId IdType="pubmed">17560245</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer. 2005;5:275–284. doi: 10.1038/nrc1590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc1590</ArticleId><ArticleId IdType="pubmed">15803154</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, et al. Coxsackievirus A16 infection induces neural cell and non-neural cell apoptosis in vitro. PLoS ONE. 2014;9:e111174. doi: 10.1371/journal.pone.0111174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111174</ArticleId><ArticleId IdType="pmc">PMC4211689</ArticleId><ArticleId IdType="pubmed">25350381</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsch M, et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575:683–687. doi: 10.1038/s41586-019-1770-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1770-6</ArticleId><ArticleId IdType="pubmed">31748744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci. Transl. Med. 2018 doi: 10.1126/scitranslmed.aau0417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau0417</ArticleId><ArticleId IdType="pmc">PMC7593827</ArticleId><ArticleId IdType="pubmed">30541787</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X, et al. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology. 2017;7:e1376156. doi: 10.1080/2162402X.2017.1376156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1376156</ArticleId><ArticleId IdType="pmc">PMC5739569</ArticleId><ArticleId IdType="pubmed">29296537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, et al. A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5. Emerg. Microbes Infect. 2018;7:185. doi: 10.1038/s41426-018-0186-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0186-y</ArticleId><ArticleId IdType="pmc">PMC6246558</ArticleId><ArticleId IdType="pubmed">30459302</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothey A, Heistermann P, Philippou S, Voigtmann R. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: Correlation with histological expression of ICAM-1 and tumour stage. Br. J. Cancer. 1998;77:801–807. doi: 10.1038/bjc.1998.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.1998.130</ArticleId><ArticleId IdType="pmc">PMC2149953</ArticleId><ArticleId IdType="pubmed">9514061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>